California Public Employees Retirement System Boosts Stake in Sarepta Therapeutics, Inc. (SRPT)

California Public Employees Retirement System raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 141,200 shares of the biotechnology company’s stock after purchasing an additional 3,100 shares during the quarter. California Public Employees Retirement System owned 0.26% of Sarepta Therapeutics worth $4,760,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. MML Investors Services LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth about $273,000. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares during the period. Northern Trust Corp increased its holdings in shares of Sarepta Therapeutics by 3.4% during the 2nd quarter. Northern Trust Corp now owns 629,504 shares of the biotechnology company’s stock worth $21,221,000 after purchasing an additional 20,680 shares during the period. Quantitative Investment Management LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth about $5,204,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Sarepta Therapeutics by 4.9% during the 2nd quarter. New York State Common Retirement Fund now owns 55,500 shares of the biotechnology company’s stock worth $1,871,000 after purchasing an additional 2,599 shares during the period. Institutional investors own 65.41% of the company’s stock.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total transaction of $575,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas S. Ingram acquired 47,058 shares of the stock in a transaction on Thursday, July 27th. The shares were purchased at an average cost of $42.50 per share, with a total value of $1,999,965.00. Following the transaction, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. Company insiders own 9.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/20/california-public-employees-retirement-system-boosts-stake-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 50.72 on Friday. The firm’s market capitalization is $3.26 billion. The firm has a 50-day moving average of $47.21 and a 200-day moving average of $37.70. Sarepta Therapeutics, Inc. has a 52-week low of $26.26 and a 52-week high of $52.67.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. The business’s quarterly revenue was up 350000.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.19) EPS. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current fiscal year.

Several research analysts have recently issued reports on the stock. Robert W. Baird restated a “buy” rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a report on Monday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $71.00 price objective on shares of Sarepta Therapeutics in a report on Friday, October 6th. Royal Bank Of Canada restated a “buy” rating and set a $64.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, October 3rd. Finally, ValuEngine downgraded shares of Sarepta Therapeutics from

Several other large investors also recently bought and sold shares of the company. MML Investors Services LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth about $273,000. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares during the period. Northern Trust Corp increased its holdings in shares of Sarepta Therapeutics by 3.4% during the 2nd quarter. Northern Trust Corp now owns 629,504 shares of the biotechnology company’s stock worth $21,221,000 after purchasing an additional 20,680 shares during the period. Quantitative Investment Management LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth about $5,204,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Sarepta Therapeutics by 4.9% during the 2nd quarter. New York State Common Retirement Fund now owns 55,500 shares of the biotechnology company’s stock worth $1,871,000 after purchasing an additional 2,599 shares during the period. Institutional investors own 65.41% of the company’s stock.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total transaction of $575,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas S. Ingram acquired 47,058 shares of the stock in a transaction on Thursday, July 27th. The shares were purchased at an average cost of $42.50 per share, with a total value of $1,999,965.00. Following the transaction, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. Company insiders own 9.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/20/california-public-employees-retirement-system-boosts-stake-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 50.72 on Friday. The firm’s market capitalization is $3.26 billion. The firm has a 50-day moving average of $47.21 and a 200-day moving average of $37.70. Sarepta Therapeutics, Inc. has a 52-week low of $26.26 and a 52-week high of $52.67.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. The business’s quarterly revenue was up 350000.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.19) EPS. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current fiscal year.

Several research analysts have recently issued reports on the stock. Robert W. Baird restated a “buy” rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a report on Monday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $71.00 price objective on shares of Sarepta Therapeutics in a report on Friday, October 6th. Royal Bank Of Canada restated a “buy” rating and set a $64.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, October 3rd. Finally, ValuEngine downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $64.34.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply